Viyash

2021年11月16日

凱雷表示，全球投資公司凱雷和總部位於海得拉巴的製藥商Viyash Life Sciences Pvt Ltd共同在印度建立了一個綜合仿製藥平台。兩家公司表示，Viyash還收購了美國Appco Pharma LLC的控股權，Appco Pharma是一家專注於美國市場的配方公司，這將有助於擴大進入美國仿製藥市場和配方能力。總部位於海德拉巴的谘詢公司Citadel Management Consulting擔任凱雷的顧問。Viyash生命科學公司於2019年成立，實收資本為5億盧比。它是由Mylan Pharmaceuticals前全球首席運營官兼印度業務主管Hari Babu博士與聯合創始人Srihari Raju Kalidindi博士共同創立的，Srihari Raju Kalidindi博士此前擔任印度製藥公司Laurus Laboratories的執行董事。Viyash是一家中間體(原料藥)製造商，其戰略是整合其他製藥中間體、原料藥和配方資產，為大型仿製藥客戶提供綜合產品。2021年6月，凱雷收購了總部位於海得拉巴的Symed Labs的控股權後，與Viyash合作，Symed Labs是一家利基api製造商，以實現向後集成。vcircle在4月份獨家報道了這筆交易，這是凱雷在印度的第二筆API投資。“通過這些收購，Viyash在印度擁有10家生產工廠，總產能約為2000公升，在美國擁有一家配方工廠，現在是印度領先的中型綜合API和配方企業之一。大多數站點是美國FDA批準的原料藥或中間體，能夠服務於受監管和半監管的市場。” In the future Viyash intends to seek further investment opportunities to build scale by targeting acquisitions with niche differentiated capabilities that complement the existing operations of the platform. It will focus on both regulated and emerging markets for generics supply, it added. “As the largest provider of generics in the world, India has solidified its position as a pharma hub. There continues to be significant potential in the market which we believe can be captured through targeted consolidation of complementary players in the generics industry," said Neeraj Bharadwaj, Co-head - Asia Healthcare and India, Carlyle Asia Partners. Dr. Hari CEO, Viyash platform, said, “Viyash will focus on providing global formulation players with end to end manufacturing capabilities. Our next phase will be to drive further integration and growth opportunities across the three businesses.” The firms said that India’s generic pharma industry is expected to gain greater share within the global market supported by its strong manufacturing and R&D capabilities, skilled technical workforce, and high proportion of FDA approved facilities. Carlyle’s investments US-based Carlyle has already been expanding its presence in India’s pharmaceutical sector. Globally, it has $293 billion of assets under management (AUM) globally as of September 30, 2021. The PE major has invested more than $14.7 billion of equity in over 80 deals in the global healthcare sector as of September 30, 2021. In India, Carlyle has invested and committed more than $5.5 billion across 44 transactions as of September 30, 2021. Last year, it acquired a majority stake in SeQuent Scientific Ltd , which makes APIs for animal healthcare, and a 20% stake in Piramal Pharma Ltd in what was its biggest healthcare deal in India. Its other healthcare investments in India include Indegene, Metropolis, Medanta and Visionary RCM Infotech. Carlyle portfolio companies today employ 300,000 plus Indian employees, agents and contractors. Meanwhile, Carlyle employs more than 1,800 people in 26 offices across five continents, the company said.